Will Moderna Stock Soar If Its COVID Vaccine Is Authorized?
Pfizer's (NYSE: PFE) share price actually fell a little after an advisory committee to the U.S. Food and Drug Administration (FDA) recommended Emergency Use Authorization (EUA) for its COVID-19 vaccine last week. Moderna (NASDAQ: MRNA) has its turn on Thursday with the same committee reviewing the EUA filing for coronavirus vaccine candidate mRNA-1273. In this Motley Fool Live video recorded on Dec. 11, 2020, healthcare and cannabis bureau chief Corinne Cardina and Fool.com writer Keith Speights discuss whether or not Moderna stock will soar if its COVID-19 vaccine wins authorization.
Source Fool.com
